Modulating inflammation and neuroprotection in multiple sclerosis. Issue 6 (5th June 2017)

• Record Type: Journal Article
• Authors: Yong, Heather; Chartier, Gabrielle; Quandt, Jacqueline
• Is Part Of: Journal of neuroscience research. Volume 96:Issue 6(2018)
• Page Start: 927
• Page End: 950
• Publication Date: 2017-06-05
• Subjects: multiple sclerosis -- neuroinflammation -- neuroprotection -- immunology -- oxidative stress -- neurodegeneration; Neurobiology -- Periodicals; 612
• DOI: 10.1002/jnr.24090
• Languages: English
• ISSNs: 0360-4012

Abstract

Abstract: Multiple sclerosis (MS) is a neurological disorder of the central nervous system with a presentation and disease course that is largely unpredictable. MS can cause loss of balance, impaired vision or speech, weakness and paralysis, fatigue, depression, and cognitive impairment. Immunomodulation is a major target given the appearance of focal demyelinating lesions in myelin‐rich white matter, yet progression and an increasing appreciation for gray matter involvement, even during the earliest phases of the disease, highlights the need to afford neuroprotection and limit neurodegenerative processes that correlate with disability. This review summarizes key aspects of MS pathophysiology and histopathology with a focus on neuroimmune interactions in MS, which may facilitate neurodegeneration through both direct and indirect mechanisms. There is a focus on processes thought to influence disease progression and the role of oxidative stress and mitochondrial dysfunction in MS. The goals and efficacy of current disease‐modifying therapies and those in the pipeline are discussed, highlighting recent advances in our understanding of pathways mediating disease progression to identify and translate both immunomodulatory and neuroprotective therapeutics from the bench to the clinic.